
U.S. stock market quick update: Incannex Healthcare up 27.23%

Incannex Healthcare rose 27.23%; Eli Lilly rose 1.11%, with a trading volume of USD 295 million; Novo Nordisk rose 3.54%, with a trading volume of USD 195 million; Johnson & Johnson rose 0.78%, with a trading volume of USD 136 million; AstraZeneca rose 0.80%, with a market capitalization of USD 251.6 billion
U.S. Stock Market Midday Update
Incannex Healthcare rose 27.23%. Based on recent important news:
-
On August 22, Incannex Healthcare announced that its board approved a stock repurchase plan of up to $20 million, driving the stock price up 36.9%.
-
On August 22, the company stated that the repurchase plan would be executed through open market purchases, reflecting its commitment to enhancing shareholder value.
-
On August 22, Incannex Healthcare rose 31.6% in pre-market trading due to the market's positive response to its capital management strategy.
Stocks with High Trading Volume in the Industry
Eli Lilly rose 1.11%, with increased trading volume. Based on recent important news:
-
On August 20, Eli Lilly announced that Anne White, Executive Vice President of Neuroscience, would retire, causing the stock price to drop 2.2%.
-
On August 20, Eli Lilly received additional approvals for indications, including sleep apnea and MASH, driving the stock price up.
-
On August 20, Deutsche Bank maintained a buy rating on Eli Lilly with a target price of $900.
Novo Nordisk rose 3.54%, with increased trading volume. Based on recent important news:
-
On August 19, Novo Nordisk announced that semaglutide was approved by the FDA for the treatment of fatty liver disease, causing the stock price to rise about 4%.
-
On August 19, Novo Nordisk reduced the out-of-pocket price of its diabetes drug NovoTide in the U.S. to $499, with the stock price closing up over 6%.
-
On August 20, the President of the China Council for the Promotion of International Trade met with the Chairman of Novo Nordisk's board to discuss expanding investments in China.
Johnson & Johnson rose 0.78%, with increased trading volume. Based on recent important news:
-
On August 21, Johnson & Johnson announced a $2 billion investment to expand its manufacturing capacity in the U.S. in response to potential drug import tariffs from the Trump administration, with the stock price rising 0.15%.
-
On August 22, Citigroup raised its target price for Johnson & Johnson to $200, boosting market confidence.
-
On August 21, Johnson & Johnson reached a cooperation agreement with Fujifilm to establish a new factory in North Carolina, further enhancing its domestic production layout.
Stocks with High Market Capitalization in the Industry
AstraZeneca rose 0.80%, with increased trading volume. Based on recent important news:
-
On August 22, AstraZeneca announced that its durvalumab was approved domestically for the treatment of certain types of breast cancer, driving the stock price up 0.80%.
-
On August 22, AstraZeneca established a research and development center in the Philippines, further consolidating its position in the Asian market.
-
On August 13, AstraZeneca's acquisition of the Chinese business of Roche was granted unconditional approval, enhancing its business layout in the Chinese market
